Please Wait...

Bioclinica debuts two divisions focused on patient engagement

Research Network and Patient Recruitment and Retention connect patients to clinical trials and sites

June 14, 2016

Bioclinica®, a specialty clinical trials technology and services provider, today announced the debut of two new divisions, creating an integrated offering focused on patient engagement. With the announcement comes the combination of Bioclinica’s extensive global clinical research site network and patient recruitment-retention engine under the Global Clinical Research business segment.

Bioclinica President and CEO John Hubbard, Ph.D., said, "Our combined offering allows us to take an integrated approach to connect eligible study participants and clinical research sites by leveraging our collective resources, expertise and technology." While Bioclinica teams work together or independently depending on the trial, Hubbard noted, "Together our comprehensive approach enables us to provide enhanced site enrollment rates surpassing the industry’s traditional site model."

Global Clinical Research President Elizabeth Thiele said, "Our goals are two-fold: improving the overall patient experience and minimizing study timelines for sponsors and CROs. We do this by recruiting the right people for the right clinical trial and then seeing them through the continuum of care at our research sites with ongoing personal interaction to enhance the patient experience."

With the 2014 merger of Bioclinica and CCBR-SYNARC, Research Network has an established system of investigator sites, making Bioclinica one of the largest global, independent site networks in the world with a top 20 pharma work history. The high-performing and high-enrolling sites have demonstrated therapeutic expertise in Alzheimer's, Cardiovascular, Osteoarthritis, Osteoporosis, Endocrinology, Diabetes, Vaccines and Pain. All Bioclinica sites are connected by best-in-class recruitment practices, global SOPs, and quality systems to generate the highest quality of data across the entire network. Each site is outfitted with state-of-the-art medical testing equipment and is staffed by physicians, nurses, study coordinators, technicians and other medical professionals and personnel with therapeutic area specialization.

"Having research teams embedded in the community is an asset to patients, sponsors and CROs," Dr. Hubbard said. "Our global-local model can minimize the number of investigative sites needed to run a clinical trial, further reducing study delivery time and cost."

The Patient Recruitment and Retention division, fully integrated into the organization since the MediciGlobal acquisition in 2015, has a 94 percent overall success rate in patient recruitment and retention programs, with more than 200 successfully completed programs in a variety of therapeutic areas. The team pioneered social media and other digital strategies for patient outreach, and developed a scalable and secure global operating platform with mobile engagement apps. More than 30 patient communities have been established, many of which are the largest in the world in their therapeutic area. "Our vibrant patient communities cross all key therapeutic areas and have a collective membership of hundreds of thousands of engaged potential study participants," Dr. Hubbard said. "These vast, active online communities are readily accessible to sponsors and CROs when a trial is ready to begin enrolling."

Thiele added, "Both the Research Network and Patient Recruitment and Retention divisions are hyper-focused on the patient and employ technology-enabled strategies. Having such strong patient engagement come from two sources within our expanding organization gives sponsors and CROs an inroad to qualified patients."

Dr. Hubbard remarked, "We have many unique synergies across our Global Clinical Research business segment and the Company overall to support patients and our customers holistically. By connecting patients and sites we are making clinical trials more accessible for people everywhere - making it a better experience for them and all research stakeholders."

Bioclinica will publically unveil the two new divisions at the DIA Annual Meeting to be held in Philadelphia on June 26-30. Find out more about Bioclinica at www.Bioclinica.com/DIA.

About Bioclinica
Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval.  The company’s cloud-based offerings include medical imaging, cardiac safety, randomization and trial supply management and optimization, electronic and eSource data capture, site payments and forecasting, pharmacovigilance, trial management, and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development.  The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia. Learn more about Bioclinica at www.Bioclinica.com and on Bioclinica LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Great advice on imaging in #clinicaltrials! https://t.co/adsP8h99Ic
bioclinica (2 days ago)
https://t.co/UZQTot9ovJ
bioclinica (2 days ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica https://t.co/fYGvqU46TI
bioclinica (2 days ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner https://t.co/MAvm6…
bioclinica (2 days ago)
RT @eClinical_Jen: Content from the FDA Webinar on Study Data Technical Conformance Guidelines is here: https://t.co/14eepSOR7b #ITTX17
bioclinica (2 days ago)
RT @CenterWatch: .@US_FDA approves first #digital pill with sensor to track #patients adherence, https://t.co/XaEctKIFRx
bioclinica (2 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices